Protalix BioTherapeutics (PLX) EPS (Basic) Growth (5y) (2015 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) EPS (Basic) Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn |
| 10 | Protalix BioTherapeutics | 217.96 Mn | 177.31 Mn | 12.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.96% |
| Mar 31, 2026 | 28.93% |
| Dec 31, 2025 | -42.55% |
| Sep 30, 2025 | 17.29% |
| Jun 30, 2025 | 15.05% |
| Mar 31, 2025 | -20.69% |
| Dec 31, 2024 | 82.69% |
| Sep 30, 2024 | 16.88% |
| Jun 30, 2024 | 43.50% |
| Mar 31, 2024 | 34.00% |
| Dec 31, 2023 | 15.33% |
| Sep 30, 2023 | 41.52% |
| Jun 30, 2023 | 19.28% |
| Mar 31, 2023 | 36.00% |
| Dec 31, 2022 | 39.26% |
| Sep 30, 2022 | 39.15% |
| Jun 30, 2022 | 36.44% |
| Mar 31, 2022 | 40.68% |
| Dec 31, 2021 | 31.67% |
| Sep 30, 2021 | 34.08% |